Are Angiotensins Involved In The Hemodynamic Changes Of Cirrhosis Patients?
Main Category: Liver Disease / HepatitisAlso Included In: Transplants / Organ Donations
Article Date: 12 Jun 2009 - 5:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
4.33 (3 votes) |
| Article Opinions: | 1 posts |
Liver cirrhosis has been recently studied in the light of the new view of the renin angiotensin system (RAS). While the angiotensin converting enzyme (ACE)-Ang 2-AT1 receptor arm contributes to liver tissue injury and fibrosis and the maintenance of basal vascular tonus in non-compensated cirrhosis, the activation of the ACE2-Ang-(1-7)-Mas receptor arm exerts anti-fibrotic actions and probably has also a role in arterial vasodilation in liver cirrhosis. In a previous study published last year in WJG by the same research group, it was shown that chronic treatment with propranolol in cirrhotic patients was characterized by marked changes in the precursors of the RAS cascade (renin and Ang 1 with repercussions on the 2 main RAS components, Ang 2 and Ang-(1-7), in the splanchnic and peripheral circulation. Therefore, the circulating profile of RAS components at different stages of liver cirrhosis and their role in hemodynamic changes of cirrhosis remained unclear.
A research article published in the World Journal of Gastroenterology addressed this issue. The research team led by Prof. Santos from the Federal University of Minas Gerais measured the circulating levels of angiotensins in patients at different stages of liver cirrhosis by radioimmunoassay, and further evaluated the influence of RAS components on hemodynamic changes during liver transplantation.
The study showed that the progression of liver dysfunction is characterized by marked changes in circulating Ang-(1-7) and Ang 2 levels. In the initial stages, there were a predominance of Ang-(1-7) rather than Ang 2. On the other hand, advanced stages of cirrhosis showed an activation of the peripheral and splanchnic RAS, and a deviation toward the formation of Ang-(1-7) in the splanchnic circulation. Furthermore, there was a positive correlation between the Ang-(1-7)/Ang 2 ratio and cardiac output and a negative correlation between this ratio and systemic vascular resistance, indicating that the final functional effects of the RAS may reflect a balance between these 2 opposing peptides.
The relationship between Ang-(1-7) and Ang 2 may play a role in hemodynamic changes of human cirrhosis. The peptide Ang-(1-7) probably predominates in the peripheral circulation in the initial stages of human cirrhosis and in the splanchnic circulation in the advanced stages, both contributing to a reduction in vascular resistance and consequently to hyperdynamic circulation. In the peripheral circulation of patients with advanced cirrhosis, when compared to the splanchnic circulation, Ang 2 probably leads to extra-splanchnic vasoconstriction. Although further studies with a larger number of patients should address the precise role of RAS in human cirrhosis, this research opens the possibility that future therapies interfering with the RAS in both the systemic and splanchnic circulation should lead to more success in the management of the hemodynamic changes in human cirrhosis.
Reference:
Vilas-Boas WW, Ribeiro-Oliveira Jr A, Pereira RM, Ribeiro RC, Almeida J, Nadu AP, Simões e Silva AC, Santos RAS. Relationship between angiotensin-(1-7) and angiotensin 2 correlates with hemodynamic changes in human liver cirrhosis.
Correspondence to:
Robson Augusto Souza dos Santos, Laboratory of Hypertension, Department of Physiology, Biological Sciences institute, Federal University of Minas Gerais, Av. Antonio Carlos, 6627, Belo Horizonte, MG, 31270-901, Brazil.
Source:
Lai-Fu Li
World Journal of Gastroenterology
Visit our liver disease / hepatitis section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/153590.php>
APA
http://www.medicalnewstoday.com/releases/153590.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Can We Use IECA To Reduce Liver Fibrosis, Without To Be Afraid Hypotension?
posted by Rafael Wingester Ribeiro de Oliveira on 27 Jan 2010 at 1:28 pmToday we know that the ECA-AngII-AT1 arm of the RAS will be one the mechanism of liver fibrosis. Then we could reduce or delay the liver fibrosis and portal hypertension with IECA, but the RAS have hemodynamic effects that need be known, in each cirrhosis stage, before try to use. This paper begin light the way. Perhaps, in compensated stage of cirrhosis, IECA would reduce/delay fibrosis without hemodynamic adverse effects.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




